Hereditary angioedema (HAE) therapeutics market is predicted to reach USD 12.4 billion at a CAGR of 17.7% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Hereditary angioedema (HAE) therapeutics market”.

The hereditary angioedema (HAE) therapeutics market is attributed to register a CAGR of 17.7% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global hereditary angioedema (HAE) therapeutics market— Takeda Pharmaceutical Company Limited (Japan), CSL (Australia), Sanofi (France), Cipla Inc. (India), BioCryst Pharmaceuticals, Inc. (US), Attune Pharmaceuticals (US), Ionis Pharmaceuticals, Inc. (US), Adverum Biotechnologies Inc. (US), Pharming (Netherlands), Arrowhead Pharmaceuticals, Inc. (US) and others.

Hereditary angioedema HAE therapeutics Market Highlights

The global hereditary angioedema (HAE) therapeutics market is estimated to register a CAGR of 17.7% during the forecast period and is projected to reach USD 12.4 billion by 2032.

The market is expanding due to factors such as increasing R&D and funding and growing demand for effective treatment options, which boost the global hereditary angioedema (HAE) therapeutics market's growth. For instance, in February 2023, Takeda Pharmaceutical Company Limited (Japan) received approval from Food Drug and Administration for TAKHZYRO to prevent hereditary angioedema (HAE) attacks in children 2 years of age and older. This is the first prophylaxis treatment approved in the US. Moreover, pharmaceutical companies are investing heavily in research and development (R&D) of new HAE therapeutics, including novel drug classes and improved formulations. Also, government initiatives and funding programs for orphan drug development and rare genetic disorders are also contributing to the advancement of HAE treatments. In 2019, the National Organization for Rare Disorders announced that approximately 7,000 rare diseases affect nearly 25 to 30 million Americans each year.

However, the high cost of treatment and the side effects of treatment limit the market's growth. Moreover, while current treatment options for HAE offer effective symptom management, they often require frequent administration and can cause side effects. This has led to an increasing interest in gene therapy as a potential curative approach for the disease. This is creating lucrative growth opportunities for the market during the forecast period.

Segment Analysis

The global hereditary angioedema (HAE) therapeutics market has been segmented based on type, treatment, drug class, route of administration, and distribution channel.

On the basis of type, the market is segmented into type I and II. The type I segment held the largest market share in 2022 due to increasing incidences of these types of HAE. These are some drugs that are in high demand. For instance, as per secondary research, KVD900, also known as Sebetralstat, is an on-demand therapy among HAE type 1 and type 2 patients.

Based on treatment, the global hereditary angioedema (HAE) therapeutics market has been segmented into prophylaxis and on-demand. Furthermore, the prophylaxis is bifurcated into long–term prophylaxis and short–term prophylaxis. The prophylaxis segment dominated the market in 2022 and was the fastest-growing segment during the forecast period. Hereditary Angioedema (HAE) prophylaxis treatment offers several significant benefits for patients with this debilitating disease. Such as reduced attack frequency and severity, improved quality of life, prevention of complications, reduced healthcare costs, increased sense of control, improved long-term health outcomes. Hence, greater advantages of prophylaxis treatment burgeoning the growth of the treatment segment.

The global hereditary angioedema (HAE) therapeutics market, based on drug class, has been segmented into C1 esterase inhibitor, selective bradykinin B2 receptor antagonist, kallikrein inhibitor, and others. The C1 esterase inhibitor segment held the largest market share in 2022 and Kallikrein inhibitor is the fastest-growing segment during the forecast period, i.e., 2023 to 2032. The increasing product launch associated with C1 esterase inhibitors is fuelling the segment growth. For instance, in August 2021, CSL Behring (US) received an approval from Food Drug and Administration for C1 esterase inhibitors namely BERINERT, indicated in the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adult and pediatric patients.

On the basis of route of administration, the global hereditary angioedema (HAE) therapeutics market has been segmented into intravenous, subcutaneous, and oral. Intravenous accounted for the largest market share, and the oral segment was the fastest-growing segment during the forecast period owing to the benefits of intravenous treatment of HAE. The benefits include rapid onset of action, high bioavailability, consistent delivery, reduced risk of side effects, and effectiveness for severe attacks.

Based on distribution channels, the global hereditary angioedema (HAE) therapeutics market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2022, and online pharmacy was the fastest-growing segment during the forecast period. This is due to factors such as increased diagnosis and awareness, prophylactic treatment, and collaboration with healthcare teams.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Hereditary angioedema HAE therapeutics Market Research Report

Regional Analysis

The global hereditary angioedema (HAE) therapeutics market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The Europe hereditary angioedema (HAE) therapeutics market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The hereditary angioedema (HAE) therapeutics market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World hereditary angioedema (HAE) therapeutics market comprises the Middle East, Africa, and Latin America.

The North American hereditary angioedema (HAE) therapeutics market held the largest market share in 2022 due to factors such as the increasing incidence of hereditary angioedema and the presence of major players such as Arrowhead Pharmaceuticals, Inc. (US), BioCryst Pharmaceuticals, Inc. (US), Attune Pharmaceuticals (US), Ionis Pharmaceuticals, Inc. (US), and Adverum Biotechnologies Inc. (US). Moreover, strategic alliances to accelerate hereditary angioedema are propelling segment growth. For instance, in May 2023, BioCryst Pharmaceuticals, Inc. (US) announced that the Public Health Institute (ISP) of Chile had approved the oral drug ORLADEYO for the prophylaxis treatment of HAE attacks in children 12 years of age or older.

Furthermore, the European hereditary angioedema (HAE) therapeutics market shows significant growth during the forecast period. This is due to the emergence of novel treatment modalities that include new treatment options, such as oral therapies and gene therapy, that are emerging and offer promising alternatives to traditional injectable therapies. These novel modalities are likely to significantly impact the HAE therapeutic market in the future. Moreover, there is an increase in partnerships among market players in order to fulfill the demands of patients. For instance, in December 2021, Sanofi (France) extended its partnership with Pharming (Netherlands) to manufacture Ruconest. This Ruconest is Pharming’s approved treatment for HAE patients who complain about swelling. 

Moreover, the Asia-Pacific hereditary angioedema (HAE) therapeutics market is representing the highest annual growth rate during the forecast period owing to expanding healthcare infrastructure because healthcare infrastructure in many Asia-Pacific countries is rapidly expanding, leading to increased access to specialized healthcare services for rare diseases like HAE. Moreover, market players are receiving approval for HAE treatment, which is propelling growth in the Asia-Pacific region. For instance, in July 2020, Cipla Inc. (India) received Food and Drug Administration approval for a generic version of the HAE drug, namely Firazyr (Icatibant Injectable Pre-Filled Syringe, 30 mg/3 mL).

Additionally, the Middle East, Africa, and Latin America regions comprised the rest of the world. The region accounted for the lowest market share in the hereditary angioedema (HAE) therapeutics market due to the lack of government funding and investment and the diagnosis & treatment of HAE. However, the increasing incidence of HAE is driving the region’s growth.

Key Findings of the Study

• The global hereditary angioedema (HAE) therapeutics market is expected to reach USD 12.4 billion by 2032, at a CAGR of 17.7% during the forecast period.


• The Europe region shows significant growth during the forecast period due to the presence of major players and increasing demand for new treatment options, such as oral therapies and gene therapy.


• Based on drug class, the C1 esterase inhibitor segment held the largest market share in 2022, with an approximate market share of 45% to 55%.


• Takeda Pharmaceutical Company Limited (Japan), CSL (Australia), Sanofi (France), Cipla Inc. (India), BioCryst Pharmaceuticals, Inc. (US), Attune Pharmaceuticals (US), Ionis Pharmaceuticals, Inc. (US), Adverum Biotechnologies Inc. (US), Pharming (Netherlands), Arrowhead Pharmaceuticals, Inc. (US) and others are the key market players.